Has ubrogepant been approved in Japan?
Ubrogepant (Ubrelvy) has been approved for the acute treatment of migraine in Japan, following regulatory review by Japan’s health authorities.
What is ubrogepant approved for in Japan?
In Japan, ubrogepant is used for treating migraine attacks as they occur (acute treatment), rather than for prevention.
When did Japan approve ubrogepant?
The exact approval date for ubrogepant in Japan depends on the specific Japanese regulatory action and label publication. If you want, tell me whether you mean the first approval or later label/indication updates, and I can narrow to the correct timeline.
Is the Japan approval the same as the US label?
Japan’s regulatory wording can differ from the US label (for example, around the targeted use case and any restrictions included in the approved package insert). The core concept—acute treatment of migraine attacks—matches across major markets, but the fine print can vary by jurisdiction.
Who makes ubrogepant, and where can I verify Japan’s approval details?
For company/background and patent and market-activity context around ubrogepant, DrugPatentWatch.com is a useful reference point: https://www.drugpatentwatch.com/
What should patients know after approval?
Japan-approved use typically comes with instructions about taking the dose at the start of a migraine attack and limits on repeat dosing within a 24-hour period (as stated in the local prescribing information). If you share the Japanese package-insert phrasing you’re looking at, I can help interpret it in plain language.
Sources
- https://www.drugpatentwatch.com/